EFFICACY OF INSULIN DEGLUDEC AFTER SWITCHING FROM INSULIN GLARGINE OR INSULIN DETEMIR IN YOUNG PERSONS WITH TYPE 1 DIABETES

被引：0

作者：

Urakami, T. ^{[1
]}

Kuwabara, R. ^{[1
]}

Habu, M. ^{[1
]}

Okuno, M. ^{[1
]}

Suzuki, J. ^{[1
]}

机构：

[1] Nihon Univ, Pediat, Tokyo, Japan

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2014年 / 106卷

关键词：

D O I：

10.1016/S0168-8227(14)70664-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PO370

引用

页码：S235 / S236

页数：2

共 50 条

[31] Real World Outcomes of Switching from Insulin Glargine (GLA) to Insulin Detemir (DET) in Medicaid Patients With Type 2 Diabetes
Cao, Zhun
Wei, Wenhui
Miao, Raymond
Thomson, Erin
[J]. DIABETES, 2013, 62 : A648 - A648
[32] Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin
Jammah, Anwar Ali
[J]. PRIMARY CARE DIABETES, 2021, 15 (01) : 132 - 137
[33] COSTS OF INSULIN GLARGINE AND INSULIN DETEMIR IN INTENSIVE INSULIN THERAPY FOR TYPE 1 DIABETES MELLITUS IN ARGENTINA: A PROBABILISTIC MODEL
Pichon-Riviere, A.
Caporale, J. E.
von Schulz-Hausmann, C.
Augustovski, F. A.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A505 - A505
[34] Intensified insulin therapy of type 2 diabetes mellitus: Insulin glargine vs. insulin detemir as basal insulin
Jungmann, Eckart
[J]. DIABETES, 2006, 55 : A118 - A118
[35] Cost Savings in Type 2 Diabetes with Insulin Glargine Compared with Insulin Detemir in the UK
Evans, Marc
Owens, David
Carroll, Dawn
Keech, Martin
[J]. DIABETES, 2009, 58 : A517 - A517
[36] Insulin degludec in clinical practice: type 1 diabetes patients switched from their basal insulin to insulin degludec
Blanquez Martinez, David
Hayon Ponce, Maria
Caballero Romero, Alvaro
Diaz Villamarin, Xando
Nieto Gomez, Pelayo
Moron Romero, Rocio
Davila Fajardo, Cristina
[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 301 - 302
[37] Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study
Taki, Kentaro
Koyanagi, Momoha
Nagaoka, Soshi
Shingaki, Tomotaka
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (12) : 1975 - 1983
[38] The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range
Elhabashy, Safinaz Adel
Sakr, Eman Mohamed
Salah, Nouran Yousef
[J]. EUROPEAN JOURNAL OF PEDIATRICS, 2023, 182 (04) : 1857 - 1868
[39] The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range
Safinaz Adel Elhabashy
Eman Mohamed Sakr
Nouran Yousef Salah
[J]. European Journal of Pediatrics, 2023, 182 : 1857 - 1868
[40] Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes
Hompesch, Marcus
Ocheltree, Scott M.
Wondmagegnehu, Eshetu T.
Morrow, Linda A.
Kollmeier, Alexa P.
Campaigne, Barbara N.
Jacober, Scott J.
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (11) : 2679 - 2687

← 1 2 3 4 5 →